2024 World Conference on Lung Cancer (WCLC) - Posters-P4.11E.24 Clinical Features of Long-Term Response (LTR) to Immune Checkpoint Inhibitors (ICIs) in Patients with Advanced or Recurrent NSCLC

P4.11E.24 Clinical Features of Long-Term Response (LTR) to Immune Checkpoint Inhibitors (ICIs) in Patients with Advanced or Recurrent NSCLC

Back to course

Pdf Summary

This study from Kindai University explored the clinical features associated with long-term response (LTR) to immune checkpoint inhibitors (ICIs) in patients with advanced or recurrent non-small cell lung cancer (NSCLC). The investigation sought to characterize patients achieving a progression-free survival of at least two years after starting ICI treatment.<br /><br />**Study Design and Patient Population:** The retrospective observational study reviewed cases treated at Kindai University Hospital between January 2015 and December 2021. Out of 792 patients with recurrent and advanced NSCLC, 388 received ICI regimens, with 57 achieving an LTR.<br /><br />**Key Findings:**<br />1. **Demographics and Characteristics:** The median age of patients was 70. Males comprised 73.7%, and 86% had a history of smoking. Most patients had adenocarcinoma (64.9%).<br />2. **Predictive Biomarkers:** High PD-L1 expression and non-squamous histology were prevalent in patients with LTR, reaffirming their predictive value for a favorable response to ICIs.<br />3. **Clinical Patterns:** Patients with LTR fell into three categories:<br />   - Those continuing ICIs for over two years.<br />   - Those discontinuing due to immune-related adverse events (irAEs).<br />   - Those completing the standard two-year ICI course.<br />   Incidence of irAEs was higher in the prolonged ICI treatment group.<br />4. **Survival Outcomes:** The five-year progression-free survival rate was 59.4%, and the overall survival rate was 91.3%.<br /><br />**Discussion:** The study suggests that characteristics such as non-squamous histology and elevated PD-L1 expression correlate with LTR in NSCLC patients. Though continuing ICIs beyond two years may increase irAEs, it might offer extended survival benefits.<br /><br />In conclusion, understanding these clinical features helps tailor treatment plans for NSCLC patients and predict which ones are more likely to benefit from long-term ICI therapy.

Asset Subtitle

Waka Dohi

Meta Tag

Speaker Waka Dohi

Topic Metastatic NSCLC – Immunotherapy

Keywords

Kindai University

immune checkpoint inhibitors

non-small cell lung cancer

long-term response

PD-L1 expression

adenocarcinoma

progression-free survival

immune-related adverse events

retrospective study

survival outcomes